https://www.selleckchem.com/products/phtpp.html
458). Our results demonstrated that patients with LAPC treated with IORT showed fewer adverse events, less treatment time, and high feasibility compared to CCRT. Although, IORT has no advantages in survival and tumor control compared with CCRT. Our results demonstrated that patients with LAPC treated with IORT showed fewer adverse events, less treatment time, and high feasibility compared to CCRT. Although, IORT has no advantages in survival and tumor control compared with CCRT. To describe the frequency of anti-RNA polymerase III antibod
Gefällt mir
Kommentar
Teilen
